INTRODUCTION: Omalizumab is indicated for the treatment of severe allergic asthma (SAA) and chronic spontaneous urticaria, although a number of studies have confirmed the effectiveness of this therapy also for other IgE-mediated diseases. AIM: To assess the impact of anti-IgE therapy on SAA and comorbid IgE-mediated allergic diseases in patients treated with omalizumab for SAA enrolled in the CAR (Czech Anti-IgE Registry). MATERIAL AND METHODS: Three hundred and ten patients with SAA treated with omalizumab were enrolled in the CAR. Two hundred and twenty-nine individuals were evaluated after 12 months of omalizumab treatment for asthma control test (ACT), examination of fractional exhaled nitric oxide (FENO), forced expiratory volume in 1 s (FEV1), the use of systemic corticosteroids, side effects of treatment and clinical effect of omalizumab on allergic comorbidities (allergic rhinitis, chronic urticaria, atopic dermatitis and food allergy). RESULTS: After 12 months of treatment with omalizumab, patients experienced a significant improvement of ACT and FEV1, reduction of FENO, use of systemic corticosteroids for asthma exacerbations and dose of maintenance oral corticosteroid therapy. The positive effect of treatment with omalizumab was observed in 82.2% of patients with allergic rhinitis, in 85.7% of patients with chronic urticaria, in 82.1% of patients with atopic dermatitis, and in 67.3% of patients with food allergy. CONCLUSIONS: In the CAR registry, patients with SAA treated with omalizumab showed a significant positive effect of anti-IgE therapy not only on the asthma control, but also on allergic comorbidities.

Department of Allergology and Clinical Immunology University Hospital Olomouc Olomouc Czech Republic

Department of Immunology Faculty of Medicine and Dentistry Palacký University Olomouc Czech Republic

See more in PubMed

Ciprandi G, Marseglia GL, Castagnoli R, et al. From IgE to clinical trials of allergic rhinitis. Expert Rev Clin Immunol. 2015;11:1321–33. PubMed

Mitchell PD, El-Gammal AI, O‘Byrne PM. Emerging monoclonal antibodies as targeted innovative therapeutic approaches to asthma. Clin Pharmacol Ther. 2016;99:38–48. PubMed

Landolina N, Levi-Schaffer F. Monoclonal antibodies: the new magic bullets for allergy: IUPHAR Review 17. Br J Pharmacol. 2016;173:793–803. PubMed PMC

El-Qutob D. Off-label uses of omalizumab. Clin Rev Allergy Immunol. 2016;50:84–96. PubMed

Global Strategy for Asthma Management and Prevention 2017 Update. http://ginasthma.org/2017-gina-report-global-strategy-for-asthma-management-and-prevention/

Fajt ML, Wenzel SE. Development of new therapies for severe asthma. Allergy Asthma Immunol Res. 2017;9:3–14. PubMed PMC

Incorvaia C, Mauro M, Russello M, et al. Omalizumab, an anti-immunoglobulin E antibody: state of the art. Drug Des Devel Ther. 2014;8:197–207. PubMed PMC

Tsabouri S, Tseretopoulou X, Priftis K, Ntzani EE. Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systemic review and meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2014;2:332–40. PubMed

Masieri S, Cavaliere C, Begvarfaj E, et al. Effects of omalizumab therapy on allergic rhinitis: a pilot study. Eur Rev Med Pharmacol Sci. 2016;20:5249–55. PubMed

Kopp MV, Hamelmann E, Zielen S, et al. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy. 2009;39:271–9. PubMed

Kamin W, Kopp MV, Erdnuess F, et al. Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously. Pediatr Allergy Immunol. 2010;21:160–5. PubMed

Vestergaard C, Deleuran M. Chronic spontaneous urticaria: latest developments in aetiology, diagnosis and therapy. Ther Adv Chronic Dis. 2015;6:304–13. PubMed PMC

Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368:924–35. PubMed

Sheinkopf LE, Rafi AW, Do LT, et al. Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc. 2008;29:530–7. PubMed

Belloni B, Ziai M, Lim A, et al. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol. 2007;120:1223–5. PubMed

Kim DH, Park KY, Kim BJ, et al. Antiimmunoglobulin E in the treatment of refractory atopic dermatitis. Clin Exp Dermatol. 2013;38:496–500. PubMed

Heil PM, Maurer D, Klein B, et al. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course – randomized, placebo-controlled and double-blind pilot study. J Dtsch Dermatol Ges. 2010;8:990–8. PubMed

Krathen RA, Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol. 2005;53:338–40. PubMed

Holm JG, Agner T, Sand C, Thomsen SF. Omalizumab for atopic dermatitis: case series and a systematic review of the literature. Int J Dermatol. 2017;56:18–26. PubMed

Wang HH, Li YC, Huang YC. Efficacy of omalizumab in patients with atopic dermatitis: a systematic review and meta-analysis. J Allergy Clin Immunol. 2016;138:1719–22. PubMed

Zink A, Gensbaur A, Zirbs M, et al. Targeting IgE in severe atopic dermatitis with a combination of immunoadsorption and omalizumab. Acta Derm Venereol. 2016;96:72–6. PubMed

Hotze M, Baurecht H, Rodriguez E, et al. Increased efficacy of omalizumab in atopic dermatitis patiens with wild-type filaggrin status and higher levels of phosphatidylcholines. Allergy. 2014;69:132–5. PubMed

Umetsu DT, Rachid R, Schneider LC. Oral immunotherapy and anti-IgE antibody treatment for food allergy. World Allergy Organ J. 2015;8:20. PubMed PMC

Wood RA, Kim JS, Lindblad R, et al. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy. J Allergy Clin Immunol. 2016;137:1103–10. PubMed PMC

Labrosse R, Graham F, Des Roches A, Bégin P. The use of omalizumab in food oral immunotherapy. Arch Immunol Ther Exp (Warsz) 2017;65:189–99. PubMed

Wood RA. Oral Immunotherapy for food allergy. J Investig Allergol Clin Immunol. 2017;27:151–9. PubMed

Feuille E, Nowak-Węgrzyn A. Oral immunotherapy for food allergies. Ann Nutr Metab. 2016;68:19–31. PubMed

Real-world effectiveness and safety of omalizumab in patients with uncontrolled severe allergic asthma from the Czech Republic